Thera-SAbDab

ANETUMAB

>   Structural Summary
TherapeuticAnetumab
TargetMSLN
Heavy ChainQVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS
Light ChainDIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb ADC
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental TechnologyMorphoSys HuCAL Phage Display
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedBayer HealthCare, ImmunoGen, MorphoSys, National Cancer Institute (USA)
Conditions Approvedna
Conditions ActiveLung cancer, Mesothelioma, Ovarian cancer, Pancreatic cancer, Solid tumours, Non-small cell lung cancer
Conditions DiscontinuedNon-small cell lung cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]